Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Figure 1

Assessment of ALK fusion status by RACE-coupled PCR sequencing. (A) Representative image showing gel electrophoresis results for first-round PCR products. Lane M, marker (200 bp ladder); lanes P, positive controls (2 lanes); lane NTC, no template control; other lanes, samples 1 through 45. (B) Representative image showing gel electrophoresis results for second-round PCR products. Lane organization is identical to (A). (C) Representative sequencing chromatograph showing ALK fusion with EML4. (D) RT-PCR validation for samples positive for ALK fusion expression. RT-PCR was used to confirm EML4-ALK fusion transcript expression in 12 samples. Sample 68 is the V5 variant (E2;A20, 408 bp). Samples 268, 171, and 320 are V9 variants (E18;A20, 2256 bp). Samples 446, 433, 138, and 347 are V1 variants (E13;A20, 1689 bp). Sample 534 is the V2 variant (E20;A20, 2445 bp). Samples 131, 421, and 431 are V3a/b variants (E6;A20 or E6 ins33;A20, 867 and 900 bp, respectively). Lane M, marker (100 bp ladder).

Back to article page

Molecular Cancer

ISSN: 1476-4598